Search - tctmd.com

Displaying 81 - 100 of 218

Sort: Relevancy | Date

$PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura$

Presentation TCT 2014

PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura

Presenter: Ajay J. Kirtane, Deepak L. Bhatt, David Hildick-Smith

September 16, 2014

Presentation TCT 2014

CON Problematic and Challenged

Presenter: Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

News Conference News TCT 2014

Symplicity Flex: No Benefit of Renal Denervation in Mild Resistant Hypertension

September 16, 2014

News Conference News TCT 2014

PRIMA: PFO Closure Fails to Reduce Number of Migraine Days at 1 Year

Yael L. Maxwell

September 16, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation

September 16, 2014

News Industry News

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

September 16, 2014

Presentation TCT 2014

Cangrelor I: Data Essentials from the Champion Trials

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Deepak L. Bhatt

September 15, 2014

Presentation TCT 2014

YES: CHAMPION PHOENIX was Convincing!

Presenter: Deepak L. Bhatt

September 14, 2014

Presentation TCT 2014

TCT 406: Renal Artery Trauma Induced by Four Different Renal Denervation Systems: A Multimodality Intraarterial Imaging Study

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Antonios Karanasos

September 14, 2014

Presentation TCT 2014

Updates and Status of the Cordis Renlane Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Felix Mahfoud

September 14, 2014

Presentation TCT 2014

Updates and Status of the ReCor Paradise Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Thomas Zeller

September 14, 2014

Presentation TCT 2014

Updates and Status of the St. Jude EnligHTN Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Updates and Status of the Boston Scientific Vessix Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Michael Boehm

September 14, 2014

Presentation TCT 2014

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, John Flack

September 14, 2014

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

News Conference News TCT 2014

PERFECT-LUTS: Endovascular Revascularization Shows Promise for Patients with ED, Lower Urinary Tract Symptoms

Yael L. Maxwell

September 14, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

September 13, 2014

Advertisement

PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura

CON Problematic and Challenged

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Symplicity Flex: No Benefit of Renal Denervation in Mild Resistant Hypertension

PRIMA: PFO Closure Fails to Reduce Number of Migraine Days at 1 Year

Experts Debate Future of Renal Denervation

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

Cangrelor I: Data Essentials from the Champion Trials

YES: CHAMPION PHOENIX was Convincing!

TCT 406: Renal Artery Trauma Induced by Four Different Renal Denervation Systems: A Multimodality Intraarterial Imaging Study

Updates and Status of the Cordis Renlane Program

Updates and Status of the ReCor Paradise Program

Updates and Status of the St. Jude EnligHTN Program

Updates and Status of the Boston Scientific Vessix Program

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

PERFECT-LUTS: Endovascular Revascularization Shows Promise for Patients with ED, Lower Urinary Tract Symptoms

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content